Mallinckrodt PLC (MNKKQ)
| Market Cap | 19.45M |
| Revenue (ttm) | 2.34B |
| Net Income (ttm) | -1.95B |
| Shares Out | 84.60M |
| EPS (ttm) | -23.17 |
| PE Ratio | n/a |
| Forward PE | 0.45 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $0.2250 |
| Previous Close | $0.2399 |
| Change ($) | -0.0149 |
| Change (%) | -6.21% |
| Day's Open | 0.2400 |
| Day's Range | 0.2200 - 0.2400 |
| Day's Volume | 1,260,864 |
| 52-Week Range | 0.0652 - 0.469 |
NEW YORK, Jan. 15, 2021 /PRNewswire/ -- The Mallinckrodt board and management has entirely abandoned shareholder interests, attempting to push through a Chapter 11 restructuring plan (their ca...
Top Ranked Value Stocks to Buy for December 21st
Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 17th
DUBLIN, Nov. 16, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced findings from a large U.S. database review of patient profiles and outcomes of patie...
DUBLIN, Nov. 16, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced results from a post hoc analysis of a retrospective chart review study of terlipress...
DUBLIN, Nov. 10, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced initiation of a retrospective chart review study, titled "Nitric Oxide Treatment In ...
DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced results from two post-hoc studies of its investigational agent terlipressin in adult...
ROCKFORD, Ill.--(BUSINESS WIRE)--In April 2017, Rockford sued Mallinckrodt and Express Scripts for antitrust violations. Rockford's lawsuit seeks to return more than $10 billion...
DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company") today announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaw...
Here's what you should know
Shares of Mallinckrodt Plc tumbled 31.2% in trading on Monday after the company said it had filed for Chapter 11 bankruptcy, in part due to a proposed billion-dollar settlement for its alleged...
Mallinckrodt Pharmaceuticals, facing billions of dollars in legal costs over its role in the nation's opiod crisis, filed for bankruptcy early Monday.
Drug manufacturer Mallinckrodt PLC (NYSE: MNK) disclosed Monday that it has voluntarily initiated Chapter 11 bankruptcy proceedings in the U.S. Bankruptcy Court to restructure its operations a...
Mallinckrodt Plc filed for bankruptcy protection on Monday in the face of lawsuits alleging it fueled the U.S. opioid epidemic and after the drugmaker lost a court battle to avoid paying highe...
Mallinckrodt Secures Broad Consensus with Key Stakeholders on Comprehensive Chapter 11 Restructuring
DUBLIN, Oct. 12, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company") today announced that it has voluntarily initiated Chapter 11 proceedings in the U.S. Bankru...
A House committee has issued detailed reports about some of their drug price increases.
Terlipressin's rejection is a huge blow to the diversification effort, but likely a delay rather than a scrapping of the entire program.
Mallinckrodt (MNK) gets a Complete Response Letter from the FDA for its NDA seeking approval for terlipressin to treat adults with hepatorenal syndrome type 1.
DUBLIN, Sept. 14, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S.
Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock?
Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.
The proposed law now goes to Gov. Gavin Newsom for his signature.
ST. LOUIS, Aug. 24, 2020 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, today announced that its Specialty Generics business has been recognized ...
Mallinckrodt BLA Submission, And Other News: The Good, Bad And Ugly Of Biopharma
STAINES-UPON-THAMES, United Kingdom, Aug. 10, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S.
Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter.
Mallinckrodt plc (MNK) CEO Mark Trudeau on Q2 2020 Results - Earnings Call Transcript
Mallinckrodt (MNK) delivered earnings and revenue surprises of 51.20% and 12.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Mallinckrodt PLC MNK, -23.00% plunged 25% in premrket trading Tuesday, reversing an earlier gain, after the specialty pharmaceutical company swung to a large net loss, but reported a...
Shares of Mallinckrodt (NYSE:MNK) decreased 24% in pre-market trading after the company reported Q2 results.
Shares of Mallinckrodt PLC MNK, +1.34% rose 0.9% in premrket trading Tuesday, after the specialty pharmaceutical company swung to a large net loss, but reported an adjusted profit that beat ex...
DUBLIN, Aug. 4, 2020 /PRNewswire/ -- Second quarter net sales of $166.5 million net of the retrospective one-time Acthar® Gel Medicaid liability; adjusted net sales of $700.9 million, a declin...
Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.
The Cardiovascular and Renal Drugs Advisory Committee of the FDA votes in favor of Mallinckrodt's (MNK) investigational agent, terlipressin, to treat adults with hepatorenal syndrome type 1.
DUBLIN, July 15, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. F...
STAINES-UPON-THAMES, United Kingdom, July 9, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will report second quarter 2020 earn...
Mallinckrodt (MNK) announces that the Cardiovascular and Renal Drugs Advisory Committee of the FDA will hold a virtual meeting to review data on terlipressin.
STAINES-UPON-THAMES, United Kingdom, June 15, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced it will present data from the pivotal Phase...
STAINES-UPON-THAMES, United Kingdom, June 11, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced publication of findings from a medical char...
Mallinckrodt (MNK) completes the rolling submission of a BLA for StrataGraft regenerative skin tissue to treat adults with deep partial-thickness thermal burns
STAINES-UPON-THAMES, United Kingdom, June 9, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that Stratatech, a Mallinckrodt company, has...
Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock?
STAINES-UPON-THAMES, United Kingdom, June 1, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will appeal a ruling by the U.S. Dis...
Frequently, buying stocks trading below their fundamental net worth can yield lucrative rewards for investors.
Shares of Mallinckrodt PLC MNK, -5.97% sank 6.7% in afternoon trading Tuesday, after J.P.
Indiscriminate sell-offs can sometimes lead to opportunities the crowds have missed. Here are three stocks that fit the criteria.
Mallinckrodt (MNK) declines on sales miss in the first quarter and a challenging outlook for the remainder of the year despite reporting an earnings beat.
Investors were disappointed by the company's Q1 results and the prospects of continued challenges from the COVID-19 pandemic.
About MNKKQ
Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesi... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 1867 |
| CEO Mark Trudeau | Employees 3,400 |
| Stock Exchange OTCMKTS | Ticker Symbol MNKKQ |
Financial Performance
In 2019, Mallinckrodt's revenue was $3.16 billion, a decrease of -1.65% compared to the previous year's $3.22 billion. Losses were -$996.50 million, -72.37% less than in 2018.